News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions


Posted on: 02/18/2011

Br J Cancer. 2011 Feb 15. [Epub ahead of print]

Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions.

Piaskowski SBienkowski MStoczynska-Fidelus EStawski RSieruta MSzybka MPapierz WWolanczyk MJaskolski DJLiberski PPRieske P.

Department of Molecular Pathology and Neuropathology, Chair of Oncology, Medical University of Lodz, Czechoslowacka 8/10 Street, Lodz 92-216, Poland.

Abstract

Background:It has recently been reported by several sources that original (i.e., present in vivo) glioma cell phenotypes or genotypes cannot be maintained in vitro. For example, glioblastoma cell lines presenting EGFR amplification cannot be established.Methods and results:IDH1 sequencing and loss of heterozygosity analysis was performed for 15 surgery samples of astrocytoma and early and late passages of cells derived from those and for 11 archival samples. We were not able to culture tumour cells presenting IDH1 mutations originating from currently proceeded 10 tumours; the same results were observed in 7 samples of archival material.Conclusion:The IDH1 mutation is expected to be almost mutually exclusive with EGFR amplification, so glioma cells with IDH1 mutations seem to represent a new group of tumour cells, which cannot be readily analysed in vitro because of their elimination. The reasons for this intriguing phenomenon should be investigated since its understanding can help to define a new therapeutic approach based on simulating in vivo conditions, responsible for tumour cells elimination in vitro. Moreover, a new model for culturing glioma cells in vitro should be designed since the current one does not provide conditions corresponding to in vivo growth.British Journal of Cancer advance online publication, 15 February 2011; doi:10.1038/bjc.2011.27 www.bjcancer.com.

PMID: 21326241 [PubMed - as supplied by publisher]

 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740